BGLC supply chain intelligence for BioNexus Gene Lab Corp.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
BioNexus Gene Lab Corp. (BGLC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| FIDELION | FIDELION | 90% | In consideration for the license, the Company agreed to pay Fidelion a total license fee of $2,000,000 in 24 equal monthly instalments and committed to purchase at least $500,000 in value of VitaGuar… |
| VENDOR-A | VENDOR-A | 90% | For three month periods ended March 31, 2026 and 2025, respectively, the suppliers who accounted for 10 % or more of the Company’s cost of sales and their balances at period ended are presented as fo… |
| VENDOR-B | VENDOR-B | 90% | For three month periods ended March 31, 2026 and 2025, respectively, the suppliers who accounted for 10 % or more of the Company’s cost of sales and their balances at period ended are presented as fo… |
| ARC-GROUP-INTERNATIONAL-LTD | ARC-GROUP-INTERNATIONAL-LTD | 80% | Under the terms of the Purchase Agreement, ARC has committed to purchase, from time to time at the Company’s discretion, up to $500,000,000 of the Company’s common stock, no par value per share ("Com… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| FIDELION-DIAGNOSTICS-PTE-LTD | FIDELION-DIAGNOSTICS-PTE-LTD | 90% | On March 11, 2026, the Company issued a Press Release which dislosed that, in connection with its Fidelion Diagnostics Pte. Ltd (“Fidelion”) transaction, Dr. Muthu Meyyappan has been appointed Chief … |
| VENDOR-A | VENDOR-A | 90% | For three month periods ended March 31, 2026 and 2025, respectively, the customers who accounted for 10 % or more of the Company’s revenue and their balances at period ended are presented as follows:… |
| VENDOR-B | VENDOR-B | 90% | For three month periods ended March 31, 2026 and 2025, respectively, the customers who accounted for 10 % or more of the Company’s revenue and their balances at period ended are presented as follows:… |
| DIAGNOSTICS-PTE-LTD | DIAGNOSTICS-PTE-LTD | 62% | on Diagnostics Pte. Ltd., which holds 392,329 shares of the Company’s common stock. Mr. Tan Lee is not a member of Fidelion’s board, and the voting and dispositive decisions with respect to those sha… |
| FIDELION-DIAGNOSTIC-PTE-LTD | FIDELION-DIAGNOSTIC-PTE-LTD | 62% | Item 13. Certain Relationships and Related Transactions, and Director Independence. Other than as stated herein, there have been no related party transactions, or any other transactions or relationsh… |
| HONG-KONG-CO-LIMITED | HONG-KONG-CO-LIMITED | 62% | t prices, the determination of fair value for impairment assessments requires significant judgment. When such investments are remeasured due to impairment or observable price changes, the resulting f… |
| MRNA-SCIENTIFIC-SDN-BHD-CHEMREX-CORPORATION | MRNA-SCIENTIFIC-SDN-BHD-CHEMREX-CORPORATION | 62% | NOTE 1 – ORGANIZATION AND BUSINESS BACKGROUND BioNexus Gene Lab Corp. (the “Company”) was incorporated in the State of Wyoming on May 12, 2017. On August 23, 2017 , the Company acquired all the outst… |
| PTE-LTD | PTE-LTD | 62% | agnostics Pte. Ltd (“Fidelion”) as consideration for the Company’s subscription of Fidelion shares. This form part of the condition under the Share Subscription and Shareholders’ Agreement “SSSA” ent… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| BGLC-DEBT | Debt stack $225,525 | 90% | Market cache reports total debt of $225,525. |